

Date: 27 February 2010

Sector: Healthcare


Industry: Biotechnology

Business Summary

Clinuvel Pharmaceuticals Limited (Clinuvel) is an Australia-based biopharmaceutical company developing its photoprotective pharmaceutical drug under the generic name afamelanotide. Afamelanotide is a man-made form of the protein which activates melanin, the skin's natural defense against ultraviolet (UV) light. Clinuvel is testing the drug in five separate categories of patients, who suffer from light related skin disorders. The Company focuses on prophylactic treatment of Erythropoietic Porphyrias in clinical trials of afamelanotide. It also focused on preventing actinic keratosis and squamous cell carcinoma of the skin in organ transplant recipients in clinical trials of afamelanotide. Clinuvel is also focused on systemic Photo Dynamic Therapy (PDT) treatments. The Company's wholly owned subsidiaries include A.C.N. 089 584 467 Pty Ltd, A.C.N. 108 768 896 Pty Ltd, Clinuvel (UK) Ltd, Clinuvel, Inc and Clinuvel AG.

Share Performance

Price (AUD): 0.26 52 Week High: 0.40 Currency: AUD
 Volume (millions): 0.3 52 Week Low: 0.18



Financial Summary

BRIEF: For the six months ended 31 December 2009, Clinuvel Pharmaceuticals Limited's revenues decreased 4% to A\$2.7M. Net loss decreased 51% to A\$4.4M. Revenues reflect a decrease in interest income. Net loss was offset by a decrease in depreciation & amortization expense, a fall in research & development cost and a fall in realized loss on disposal of investment. The Company is engaged in biopharmaceutical business.

Valuation Ratios

Price/Earnings	--
Price/Sales	27.65
Price/Book	2.21
Price/Cashflow	--

Per Share Data

Earnings	(0.05)
Sales	0.01
Book Value (MRI)	0.12
Cash Flow	(0.05)
Cash (MRI)	0.12

Profitability Ratios (%)

Gross Margin	--
Operating Margin	(529.19)
Net Profit Margin	(529.19)

Management Effectiveness (%)

Return on Equity (MRI)	(34.60)
Return on Assets (MRI)	(31.83)
Return on Investment (MRI)	(34.59)

Financial Strength

Quick Ratio (MRI)	8.93
Current Ratio (MRI)	8.93
LT Debt/Equity (MRI)	0.00
Total Debt/Equity (MRI)	0.00

Dividend Information

Dividend Yield (%)	--
Dividend per Share (MRI)	0.00
Payout Ratio (MRI)	--

TTM: Trailing Twelve Months; MRQ: Most Recent Quarter; MRI: Most Recent Interim.
 Latest fiscal year: 2009; Most recent quarter: ; Fiscal year end month: June;
 All Ratios are calculated for the latest fiscal year end unless otherwise indicated.
 Data Source: Reuters Fundamentals



REUTERS




Clinuvel Pharmaceuticals Ltd

Level 13 , 1 Collins Street
 Melbourne
 VIC 3000
 Australia

Darren Keamy (CFO)

<http://www.clinuvel.com/>


P/E: --
 Employees: 16
 Market Cap: 80.33 (Millions)
 Shares Outstanding: 303.15
 Float: 210.70



Key Ratios & Statistics

Financial Strength

	12 Mo Jun 07	12 Mo Jun 08	12 Mo Jun 09	MRI	3 Year Average
Quick Ratio	25.78	16.34	8.35	8.93	16.82
Current Ratio	26.90	16.88	8.93	8.93	17.57
LT Debt/Equity	0.00	0.00	0.00	0.00	0.00
Total Debt Equity	0.00	0.00	0.00	0.00	0.00



Quick Ratio: Cash plus Short Term Investments plus Accounts Receivable divided by the Total Current Liabilities for the same period. **Current Ratio:** Total Current Assets divided by Total Current Liabilities for the same period. **Long Term Debt To Total Equity:** Total Long Term Debt divided by Total Shareholder Equity. **Total Debt to Total Equity:** Total Debt divided by Total Shareholder Equity for the same period.

Financial Strength looks at business risk. The stronger a company is from a financial standpoint, the less risky it is. The Quick Ratio compares cash and short-term investments (investments that could be converted to cash very quickly) to the financial liabilities they expect to incur within a year's time.


The Current Ratio compares year-ahead liabilities to cash on hand now plus other inflows (e.g. Accounts Receivable) the company is likely to realize over that same twelve-month period.

Current Ratio	8.93
Total Current Assets	40.59
Total Current Liabilities	4.54

The Long Term Debt/Equity Ratio looks at the company's capital base. A ratio of 1.00 means the company's long-term debt and equity are equal. The Total Debt/Equity Ratio includes long-term debt and short term debt.

Profitability

	12 Mo Jun 07	12 Mo Jun 08	12 Mo Jun 09	3 Year Average
Gross Margin (%)	100.00	--	--	100.00
Operating Margin (%)	(3,242.40)	--	--	(3,242.40)
Net Profit Margin (%)	(359.28)	(341.08)	(529.19)	(409.85)
Interest Coverage	--	--	--	--



Gross Margin: This value measures the percent of revenue left after paying all direct production expenses. It is calculated as Revenue minus the Cost of Goods Sold divided by the Revenue and multiplied by 100. **Operating Margin:** This value measures the percent of revenues remaining after paying all operating expenses. It is calculated as Operating Income divided by the Total Revenue, multiplied by 100. **Net Profit Margin:** Also known as Return on Sales, this value is the Income After Taxes divided by Total Revenue for the same period and is expressed as a percentage. **Interest Coverage:** The Operating Income divided by the company's interest obligations.

These ratios realize overall profitability, or the bottom line.

Gross Margin (%)	-- (%)
$\frac{\text{Gross Profit}}{\text{Revenue}} \times 100$	$\frac{0.00}{0.00} \times 100$

Gross Margin shows the amount of revenue left over after deducting direct costs of producing the goods or services. Operating Profit and Operating Margin trace the progress revenue down to another important level. From gross profit, we now subtract indirect costs, often referred to as overhead e.g. facilities and salaries associated with headquarters operations.

Finally, Profit Margin shows you how much of each revenue dollar is left after all costs, of any kind, are subtracted. These other costs include such items as interest on corporate debt and income taxes.

TTM: Trailing Twelve Months; **MRQ:** Most Recent Quarter; **MRI:** Most Recent Interim.

Latest fiscal year: 2009; Most recent quarter: ; Fiscal year end month: June;


All Ratios are calculated for the latest fiscal year end unless otherwise indicated.

Data Source: Reuters Fundamentals

Key Ratios & Statistics (cont.)

Management Effectiveness (%)

	12 Mo Jun 07	12 Mo Jun 08	12 Mo Jun 09	3 Year Average
Return on Equity %	(23.12)	(25.01)	(34.60)	(27.58)
Return on Assets %	(21.62)	(23.87)	(31.83)	(25.77)
Return on Investments %	(23.11)	(25.01)	(34.59)	(27.57)



Return On Equity: Income Available to Common Stockholders divided by the Common Equity and expressed as a percentage. **Return on Assets:** This value is the Income After Taxes divided by the Average Total Assets, expressed as a percentage. **Return on Investments:** Income after taxes divided by the average total long term debt, other long term liabilities and shareholders equity, and expressed as a percentage.

A company's ability to operate profitably can be measured directly by measuring its return on assets. ROA (Return On Assets) is the ratio of a company's net profit to its total assets, expressed as a percentage.

$$\text{Return on Assets (\%)} = \frac{\text{Income After Taxes}}{\text{Average Total Assets}} \times 100 = \frac{(15.37)}{48.29} \times 100 = (31.83) (\%)$$

ROA measures how well a company's management uses its assets to generate profits. It is a better measure of operating efficiency than ROE, which only measures how much profit is generated on the shareholders equity but ignores debt funding. This ratio is particularly relevant for banks which typically have huge assets.

Dividend Information

	12 Mo Jun 07	12 Mo Jun 08	12 Mo Jun 09	3 Year Growth	3 Year Average
Payout Ratio (%)	(0.00)	(0.00)	(0.00)		--
Dividend Per Share	0.00	0.00	0.00		

Dividend Per Share: Common Stock Cash Dividends divided by the shares outstanding. **Payout Ratio:** This ratio is the percentage of the Primary/Basic Earnings Per Share Excluding Extraordinary Items paid to common stockholders in the form of cash dividends.

The annual dividend is the total amount(AUD) of dividends you could expect to receive if you held the stock for a year (assuming no change in the company's dividend policy).


$$\text{Payout Ratio (\%)} = \frac{\text{Dividend Per Share}}{\text{Primary EPS}} \times 100 = \frac{0.00}{(0.05)} \times 100 = (0.00) (\%)$$

The dividend yield is the indicated annual dividend rate expressed as a percentage of the price of the stock, and could be compared to the coupon yield on a bond. The Payout Ratio tells you what percent of the company's earnings have been given to shareholders as cash dividends. A low payout ratio indicates that company has chosen to reinvest most of the profits back into the business.

Key Ratios & Statistics (cont.)

Per Share Data

	12 Mo Jun 07	12 Mo Jun 08	12 Mo Jun 09	Interim	3 Year Growth
Earning Per Share	(0.04)	(0.05)	(0.05)		
Sales Per Share	0.01	0.01	0.01		0.00
Book Value	0.22	0.17	0.12	**0.12	0.17
Cash Flow	(0.04)	(0.05)	(0.05)		
Cash Per Share	0.21	0.17	0.12	**0.12	0.29



EPS Excluding Extraordinary Items: This is the adjusted income available to Common divided by the diluted weighted average shares outstanding. **Sales (Revenue) Per Share:** Total Revenue divided by the Average Diluted Shares Outstanding. **Book Value Per Share:** This is defined as the Common Shareholder's Equity divided by the Shares Outstanding. **Cash Flow:** Cash Flow is defined as the sum of Income After Taxes minus Preferred Dividends and General Partner Distributions plus Depreciation, Depletion and Amortization. **Cash Per Share:** This is the Total Cash plus Short Term Investments divided by the Shares Outstanding.

The most important Per-Share Data item is Earnings Per Share. That's because ultimately, the price of your stock is related in some way to the value of the stream of earnings attributable to that share.

Earnings Per Share	(0.05)
Adjusted Income Avail. to Common Shareholders	(15.37)
Diluted Weighted Average Shares	303.15

This section also includes the amount of Cash Per Share the company had at the time of its most recent quarterly or annual report. Most of the time, this number will be far below the stock price. In a healthy industrial company, a Cash Per Share figure that is close the stock price might suggest that investors are underestimating the worth of the company's ongoing business, thereby creating an interesting investment opportunity for you.

Consensus Estimates

Analyst Recommendations & Revisions	Current	As of 1 Week Ago	As of 4 Weeks Ago	As of 8 Weeks Ago	As of 13 Weeks Ago
Buy	1	1	1	1	1
Outperform	0	0	0	0	0
Hold	0	0	0	0	0
Underperform	0	0	0	0	0
Strong Sell	0	0	0	0	0
Mean Rating	1.0	1.0	1.0	1.0	1.0

Consensus Estimate Trends	Current	As of 1 Week Ago	As of 4 Weeks Ago	As of 8 Weeks Ago	As of 13 Weeks Ago
Sales (Millions)					
Year Ending Jun 09	1.1	--	--	--	--
Year Ending Jun 10	0.0	0.0	--	--	--
Earnings¹ (Per share)					
Year Ending Jun 10	(4.7)	(4.7)	(4.7)	(4.7)	(4.7)
Year Ending Jun 11	(2.1)	(2.1)	(2.1)	(2.1)	(1.8)

Consensus Estimate Analysis	No. of Estimates	Mean Estimate	High Estimate	Low Estimate
Sales (Millions)				
Year Ending Jun 09	1	1.1	1.1	1.1
Year Ending Jun 10	1	0.0	0.0	0.0
Earnings¹ (Per share)				
Year Ending Jun 10	1	(4.7)	(4.7)	(4.7)
Year Ending Jun 11	1	(2.1)	(2.1)	(2.1)

Quarter Historical Surprises	Estimate	Actual	Difference	Surprise (%)
Sales (Millions)				
Year Ending Jun 09	1.10	0.00	1.10	100.00
Earnings¹ (Per share)				
Year Ending Jun 09	(5.40)	(5.10)	0.30	(5.56)
Dividends (Per Share)				
Year Ending Jun 09	0.00	0.00	0.00	--


¹ Earnings per share (Adjusted to exclude exceptional items)

² Net Profit (Adjusted to exclude exceptional items)

Consensus Recommendation
BUY

Company Fiscal Year End Month
June






Last Updated
27 February 2010



(AUD Millions)

Annual Income Statement





	Type of Update	CLA	UPD	UPD
		(AUD Millions) 12Months 30 Jun 07	(AUD Millions) 12Months 30 Jun 08	(AUD Millions) 12Months 30 Jun 09
Total Revenue		2.6	4.3	2.9
Cost of Revenue, Total		--	--	--
Gross Profit		0.3	0.0	--
Selling/General/Admin. Expenses		7.6	11.4	8.3
Research & Development		4.0	7.6	10.0
Depreciation/Amortization		--	--	--
Interest Expense/Income Net Op.		--	--	--
Unusual Income/Expense		0.1	0.0	0.0
Other Operating Expenses, Total		--	--	--
Total Operating Expense		11.7	19.0	18.3
Operating Income		(9.2)	(14.7)	(15.4)
Interest Expense/Income Net Non Op.		--	--	--
Gain/(Loss) on Sale of Assets		--	--	--
Other, Net		--	--	--
Income Before Tax		(9.2)	(14.7)	(15.4)
Income Tax - Total		0.0	0.0	0.0
Income After Tax		(9.2)	(14.7)	(15.4)
Minority Interest		--	--	--
Equity In Affiliates		--	--	--
U.S. GAAP Adjustment		--	--	--
Net Income Before Extra. Items		(9.2)	(14.7)	(15.4)
Accounting Change		--	--	--
Discontinued Operations		--	--	--
Extraordinary Item		--	--	--
Tax on Extraordinary Items		--	--	--
Net Income		(9.2)	(14.7)	(15.4)
Preferred Dividends		--	--	--
General Partner's Distributions		--	--	--
Inc. Avail. to Common Excl. Extra. Items		(9.2)	(14.7)	(15.4)
Inc. Avail. to Common Incl. Extra. Items		(9.2)	(14.7)	(15.4)
Basic Weighted Average Shares		248.2	302.4	303.1
Basic EPS Excl. Extra. Items		(0.037)	(0.048)	(0.051)
Basic EPS Incl. Extra. Items		(0.037)	(0.048)	(0.051)
Dilution Adjustment		0.000	0.000	0.000
Diluted Net Income		(9.176)	(14.656)	(15.373)
Diluted Weighted Average Shares		248.220	302.380	303.149
Diluted EPS Excl. Extra. Items		(0.037)	(0.048)	(0.051)
Diluted EPS Incl. Extra. Items		(0.037)	(0.048)	(0.051)
Div's per Share - Common Stock		0.000	0.000	0.000
Gross Dividends - Common Stock		0.000	0.000	0.000
Interest Expense, Supplemental		--	--	--
Interest Capitalized, Supplemental		--	--	--
Depreciation, Supplemental		0.065	0.094	0.095
Total Special Items		0.121	0.030	0.004
Normalized Income Before Tax		(9.055)	(14.626)	(15.369)
Effect of Special Items on Inc. Taxes		0.000	0.000	0.000
Inc. Taxes Excl. Impact Special Items		0.000	0.000	0.000
Normalized Income After Tax		(9.055)	(14.626)	(15.369)
Normalized Income Available to Common		(9.055)	(14.626)	(15.369)
Basic Normalized EPS		(0.036)	(0.048)	(0.051)
Diluted Normalized EPS		(0.036)	(0.048)	(0.051)
Auditor		GTTT	GTTT	GNTH
Auditor Opinion		UNO	UNO	UNO
Source Document		ARS	ARS	ARS



Annual Balance Sheet





	Type of Update	CLA	UPD	UPD
		(AUD Millions) 30 Jun 07	(AUD Millions) 30 Jun 08	(AUD Millions) 30 Jun 09
Cash		33.8	0.8	1.6
Cash and Equivalents		--	--	--
Short Term Investments		28.5	50.0	36.2
Cash and Short Term Investments		62.4	50.8	37.8
Accounts Receivable(Trade), Net		0.1	0.2	0.0
Notes Receivable - Short Term		--	--	--
Other Receivables		0.2	0.5	0.2
Total Receivables, Net		0.2	0.6	0.2
Total Inventory		0.0	--	--
Prepaid Expenses		1.8	1.4	2.3
Other Current Assets		0.9	0.3	0.3
Total Current Assets		65.3	53.1	40.6
Property/Plant/Equipment - Gross		0.6	0.7	0.7
Accumulated Depreciation		(0.3)	(0.3)	(0.3)
Property/Plant/Equip., Net		0.3	0.4	0.4
Goodwill, Net		--	--	--
Intangibles, Net		2.2	1.4	0.7
Long Term Investments		--	--	--
Note Receivable - Long Term		--	--	--
Other Long Term Assets, Total		--	--	--
Other Assets, Total		--	--	--
Total Assets		67.8	55.0	41.6
Accounts Payable		1.6	0.7	2.1
Payable/Accrued		--	--	--
Accrued Expenses		--	--	--
Notes Payable/Short Term Debt		0.0	0.0	0.0
Current Port. LT Debt/Capital Leases		--	--	--
Other Current Liabilities, Total		0.8	2.4	2.5
Total Current Liabilities		2.4	3.1	4.5
Long Term Debt		--	--	--
Capital Lease Obligations		--	--	--
Total Long Term Debt		0.0	0.0	0.0
Total Debt		0.0	0.0	0.0
Deferred Income Tax		--	--	--
Minority Interest		--	--	--
Other Liabilities, Total		0.0	0.0	0.0
Total Liabilities		2.4	3.2	4.6
Redeemable Preferred Stock		--	--	--
Preferred Stock(Non Redeemable), Net		--	--	--
Common Stock		112.8	113.2	113.2
Additional Paid-In Capital		--	0.1	0.0
Retained Earnings/Accum. Deficit		(47.4)	(63.2)	(78.3)
Treasury Stock - Common		--	--	--
ESOP Debt Guarantee		--	--	--
Unrealized Gain/Loss		--	--	--
Other Equity, Total		--	1.7	2.2
Total Equity		65.4	51.8	37.1
Total Liability & Shareholders' Equity		67.8	55.0	41.6
Total Common Shares Outstanding		302.1	303.1	303.1
Total Preferred Stock Shares Outs.		--	--	--

Auditor	GTTT	GTTT	GNTH
Auditor Opinion	UNO	UNO	UNO
Source Document	ARS	ARS	ARS



Annual Cash Flow Statement

Type of Update	UPD	UPD	UPD
	(AUD Millions) 12Months 30 Jun 07	(AUD Millions) 12Months 30 Jun 08	(AUD Millions) 12Months 30 Jun 09
Net Income/Starting Line	--	--	--
Depreciation/Depletion	--	--	--
Amortization	--	--	--
Deferred Taxes	--	--	--
Non-Cash Items	--	--	--
Cash Receipts	0.4	0.3	0.2
Cash Payments	(11.0)	(11.5)	(14.1)
Cash Taxes Paid	--	--	--
Cash Interest Paid	--	--	--
Changes in Working Capital	2.4	4.0	2.9
Total Cash from Operating Activities	(8.2)	(7.2)	(11.0)
Capital Expenditures	(0.4)	(0.2)	(0.0)
Other Investing Cash Flow Items, Total	(26.0)	(0.5)	6.6
Total Cash from Investing Activities	(26.5)	(0.7)	6.5
Financing Cash Flow Items	(1.8)	(0.1)	0.0
Total Cash Dividends Paid	--	--	--
Insurance/Retirement of Stock, Net	61.8	0.1	0.1
Insurance/Retirement of Debt, Net	--	--	--
Total Cash from Financing Activities	60.0	0.0	0.1
Foreign Exchange Effects	(0.1)	(0.2)	0.3
Net Change in Cash	25.2	(8.1)	(4.0)
Depreciation, Supplemental	0.1	0.1	0.1
Cash Interest Paid, Supplemental	--	--	--
Cash Taxes Paid, Supplemental	--	--	--
Auditor	WIBU	GTTT	GNTH
Auditor Opinion	UNO	UNO	UNO
Source Document	ARS	ARS	ARS



Interim Income Statement

Type of Update

	(AUD Millions) N/A	(AUD Millions) N/A	(AUD Millions) N/A	(AUD Millions) N/A	(AUD Millions) N/A
Total Revenue	--	--	--	--	--
Cost of Revenue, Total	--	--	--	--	--
Gross Profit	--	--	--	--	--
Selling/General/Admin. Expenses	--	--	--	--	--
Research & Development	--	--	--	--	--
Depreciation/Amortization	--	--	--	--	--
Interest Expense/Income Net Op.	--	--	--	--	--
Unusual Income/Expense	--	--	--	--	--
Other Operating Expenses, Total	--	--	--	--	--
Total Operating Expense	--	--	--	--	--
Operating Income	--	--	--	--	--
Interest Expense/Income Net Non Op.	--	--	--	--	--
Gain/(Loss) on Sale of Assets	--	--	--	--	--
Other, Net	--	--	--	--	--
Income Before Tax	--	--	--	--	--
Income Tax - Total	--	--	--	--	--
Income After Tax	--	--	--	--	--
Minority Interest	--	--	--	--	--
Equity In Affiliates	--	--	--	--	--
U.S. GAAP Adjustment	--	--	--	--	--
Net Income Before Extra. Items	--	--	--	--	--
Accounting Change	--	--	--	--	--
Discontinued Operations	--	--	--	--	--
Extraordinary Item	--	--	--	--	--
Tax on Extraordinary Items	--	--	--	--	--
Net Income	--	--	--	--	--
Preferred Dividends	--	--	--	--	--
General Partner's Distributions	--	--	--	--	--
Inc. Avail. to Common Excl. Extra. Items	--	--	--	--	--
Inc. Avail. to Common Incl. Extra. Items	--	--	--	--	--
Basic Weighted Average Shares	--	--	--	--	--
Basic EPS Excl. Extra. Items	--	--	--	--	--
Basic EPS Incl. Extra. Items	--	--	--	--	--
Dilution Adjustment	--	--	--	--	--
Diluted Net Income	--	--	--	--	--
Diluted Weighted Average Shares	--	--	--	--	--
Diluted EPS Excl. Extra. Items	--	--	--	--	--
Diluted EPS Incl. Extra. Items	--	--	--	--	--
Div's per Share - Common Stock	--	--	--	--	--
Gross Dividends - Common Stock	--	--	--	--	--
Interest Expense, Supplemental	--	--	--	--	--
Interest Capitalized, Supplemental	--	--	--	--	--
Depreciation, Supplemental	--	--	--	--	--
Total Special Items	--	--	--	--	--
Normalized Income Before Tax	--	--	--	--	--
Effect of Special Items on Inc. Taxes	--	--	--	--	--
Inc. Taxes Excl. Impact Special Items	--	--	--	--	--
Normalized Income After Tax	--	--	--	--	--
Normalized Income Available to Common	--	--	--	--	--
Basic Normalized EPS	--	--	--	--	--
Diluted Normalized EPS	--	--	--	--	--

Source Document
Fiscal Period

Interim Accounts - Balance Sheet

Type of Update

	(AUD Millions) N/A	(AUD Millions) N/A	(AUD Millions) N/A	(AUD Millions) N/A	(AUD Millions) N/A
Cash	--	--	--	--	--
Cash and Equivalents	--	--	--	--	--
Short Term Investments	--	--	--	--	--
Cash and Short Term Investments	--	--	--	--	--
Accounts Receivable(Trade), Net	--	--	--	--	--
Notes Receivable - Short Term	--	--	--	--	--
Other Receivables	--	--	--	--	--
Total Receivables, Net	--	--	--	--	--
Total Inventory	--	--	--	--	--
Prepaid Expenses	--	--	--	--	--
Other Current Assets	--	--	--	--	--
Total Current Assets	--	--	--	--	--
Property/Plant/Equipment - Gross	--	--	--	--	--
Accumulated Depreciation	--	--	--	--	--
Property/Plant/Equip., Net	--	--	--	--	--
Goodwill, Net	--	--	--	--	--
Intangibles, Net	--	--	--	--	--
Long Term Investments	--	--	--	--	--
Note Receivable - Long Term	--	--	--	--	--
Other Long Term Assets, Total	--	--	--	--	--
Other Assets, Total	--	--	--	--	--
Total Assets	--	--	--	--	--
Accounts Payable	--	--	--	--	--
Payable/Accrued	--	--	--	--	--
Accrued Expenses	--	--	--	--	--
Notes Payable/Short Term Debt	--	--	--	--	--
Current Port. LT Debt/Capital Leases	--	--	--	--	--
Other Current Liabilities, Total	--	--	--	--	--
Total Current Liabilities	--	--	--	--	--
Long Term Debt	--	--	--	--	--
Capital Lease Obligations	--	--	--	--	--
Total Long Term Debt	--	--	--	--	--
Total Debt	--	--	--	--	--
Deferred Income Tax	--	--	--	--	--
Minority Interest	--	--	--	--	--
Other Liabilities, Total	--	--	--	--	--
Total Liabilities	--	--	--	--	--
Redeemable Preferred Stock	--	--	--	--	--
Preferred Stock(Non Redeemable), Net	--	--	--	--	--
Common Stock	--	--	--	--	--
Additional Paid-In Capital	--	--	--	--	--
Retained Earnings/Accum. Deficit	--	--	--	--	--
Treasury Stock - Common	--	--	--	--	--
ESOP Debt Guarantee	--	--	--	--	--
Unrealized Gain/Loss	--	--	--	--	--
Other Equity, Total	--	--	--	--	--
Total Equity	--	--	--	--	--
Total Liability & Shareholders' Equity	--	--	--	--	--
Total Common Shares Outstanding	--	--	--	--	--
Total Preferred Stock Shares Outs.	--	--	--	--	--

Source Document
Fiscal Period

Interim Accounts - Cash Flow Statement

Type of Update

	(AUD Millions) N/A	(AUD Millions) N/A	(AUD Millions) N/A	(AUD Millions) N/A	(AUD Millions) N/A
Net Income/Starting Line	--	--	--	--	--
Depreciation/Depletion	--	--	--	--	--
Amortization	--	--	--	--	--
Deferred Taxes	--	--	--	--	--
Non-Cash Items	--	--	--	--	--
Cash Receipts	--	--	--	--	--
Cash Payments	--	--	--	--	--
Cash Taxes Paid	--	--	--	--	--
Cash Interest Paid	--	--	--	--	--
Changes in Working Capital	--	--	--	--	--
Total Cash from Operating Activities	--	--	--	--	--
Capital Expenditures	--	--	--	--	--
Other Investing Cash Flow Items, Total	--	--	--	--	--
Total Cash from Investing Activities	--	--	--	--	--
Financing Cash Flow Items	--	--	--	--	--
Total Cash Dividends Paid	--	--	--	--	--
Insurance/Retirement of Stock, Net	--	--	--	--	--
Insurance/Retirement of Debt, Net	--	--	--	--	--
Total Cash from Financing Activities	--	--	--	--	--
Foreign Exchange Effects	--	--	--	--	--
Net Change in Cash	--	--	--	--	--
Depreciation, Supplemental	--	--	--	--	--
Cash Interest Paid, Supplemental	--	--	--	--	--
Cash Taxes Paid, Supplemental	--	--	--	--	--

Source Document
Fiscal Period

Further Information

Internet Information

Home Page:	http://www.clinuvel.com/
News Releases:	http://www.clinuvel.com/en/investors/news-and-media/
Investor Relations:	http://www.clinuvel.com/en/investors/
Financial Information:	http://www.clinuvel.com/en/investors/company-reports/annual-reports/
Corporate History/Profile:	http://www.clinuvel.com/en/corporate/
Executives:	http://www.clinuvel.com/en/corporate/people/
Products/Services:	http://www.clinuvel.com/en/afamelanotide/about-afamelanotide/
Employment Opportunities:	http://www.clinuvel.com/en/corporate/work-opportunities/

Officers

Brenda Shanahan	Non-Executive Chairman of the Board
Phillipe Wolgen	Chief Executive Officer, Managing Director, Director
Helmer Agersborg	Executive Deputy Chairman of the Board, Chief Scientific Officer
Darren Keamy	Chief Financial Officer, Company Secretary
Dennis Wright	Vice President - Scientific Affairs
Roger Aston	Non-Independent Non-Executive Director
Lawrence Wood	Non-Executive Director
Stanley McLiesh	Non-Executive Independent Director

Clinuvel Pharmaceuticals Ltd Group Headquarters: Level 13 , 1 Collins Street, Melbourne, VIC 3000, Australia, Darren Keamy (CFO)

Unless otherwise stated, this Report and its contents are © Thomson Reuters 2010. All rights reserved (including without limitation copyright and rights in databases). Republication or redistribution of Thomson Reuters content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks and trademarks of Thomson Reuters and its affiliated companies.

This Report is provided solely for information and Thomson Reuters hereby grants to the recipient a personal, read-only license for such purpose. Any other use of this Report and of its contents is expressly prohibited.

This Report is not an invitation or inducement to engage in investment activity, nor is it an offer to buy or sell securities, and does not constitute tax, investment or other advice. Neither this Report nor the information contained in it should be relied upon.

Reuters does not aim to provide advice which is appropriate to the individual circumstances of the private investor. Use of this Report is not a substitute for obtaining proper investment advice from an authorized investment professional. While the information contained herein has been obtained from sources deemed reliable, neither Reuters nor any party through whom the reader obtains this Report guarantees that it is accurate or complete or makes any warranty or representation with regard to the results obtained from its use. In addition, the information contained in this Report may become inaccurate as a result of the passage of time and should therefore be read for historical information only. Potential investors are urged to consult their own authorized investment professional before entering into an investment agreement.

Reuters makes no warranty or representation that this Report or its contents are current or that they have been updated based on changes in the economic market or other factors. In particular, but without limiting the preceding sentence, statements of fact or opinion made by Reuters in this Report may not be up-to-date and may not represent the current opinion of Reuters.